OMRX yields 2000000.00% · ABBV yields 3.12%● Live data
📍 OMRX pulled ahead of the other in Year 1
Combined, OMRX + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of OMRX + ABBV for your $10,000?
Orthometrix, Inc. develops technologies, procedures, and devices to help increase musculoskeletal mobility, as well as non-invasive technologies to treat the pain associated with osteoarthritis, plantar fasciitis, and other musculoskeletal conditions that reduce mobility. The company markets, sells, and services peripheral quantitative computed tomography bone and muscle measurement systems for research and clinical applications; patented motorized exercise systems for rehabilitation, physical therapy, and sports medicine based on patented vibration technology; human performance measurement systems for monitoring improvement in power and mobility; and extracorporeal shock wave therapy systems for non-invasive treatment of pain associated with plantar fasciitis. It also markets, sells, and services patented motorized exercise systems to professional teams, fitness centers, gyms, sports clubs, and wellness-conscious general public. The company offers bone and muscle diagnostic, bone and muscle research, rehabilitation/physical therapy, sports and fitness, and home products. It serves healthcare, veterinary, and sports and fitness markets in the United States and internationally. The company was formerly known as Norland Medical Systems, Inc. and changed its name to Orthometrix, Inc. in April 2002. Orthometrix, Inc. was founded in 1993 and is headquartered in Naples, Florida.
Full OMRX Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.